Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Research in Brief1484
EASL Congress 2024514
GORD: pain, PPIs, and preciseness472
Research in Brief432
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design427
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11415
Lucky: Learning to Live Again386
Viral hepatitis: time for action312
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply308
Treatment withdrawal in Crohn's disease: slowly becoming clearer305
Immune checkpoint inhibitors in colorectal cancer: dream and reality271
Trends in alcohol-specific deaths in the UK and industry responses271
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship257
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension212
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study212
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled210
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma210
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30204
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic204
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy203
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium201
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives199
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t196
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial179
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial178
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial164
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis160
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement153
Global multi-stakeholder endorsement of the MAFLD definition151
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study146
ACG 2024141
Water and sanitation for all139
Rare cause of dysphagia in a young woman139
Bringing organ preservation closer for selected patients with rectal cancer132
The potential of ctDNA in locoregional therapies for colorectal cancer128
Addressing the rise of early-onset colorectal cancer127
Management of portal vein thrombosis in cirrhosis126
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis124
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere122
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply122
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)117
Availability of point-of-care HBV tests in resource-limited settings115
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?113
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial111
Sex and gender in inflammatory bowel disease outcomes and research109
Resmetirom for NASH: balancing promise and prudence108
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review103
All roads lead to the gut–brain microbiome network102
Research in Brief100
Local and systemic therapy in liver cancer: the quest for synergy100
Idiopathic gastroparesis consensus misses the patient's voice99
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply98
Has the time come for a systematic top-down approach in Crohn's disease?97
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–4794
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial94
Long-term VEDOKIDS results: implications for practice and research94
Uptick of food allergies in recent years—real or epiphenomenon?94
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada94
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study93
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study93
Britta Siegmund: answering the big questions in IBD93
Management of malignant bowel obstruction – Authors' reply92
Research in Brief91
Robotic versus laparoscopic surgery for middle and low rectal cancer90
The Year My Life Went Down the Toilet90
Lifting the minority tax in gastroenterology and hepatology87
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist86
Hypovolaemic phlebotomy for hepatic resection82
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations80
Managing inflammatory bowel disease: what to do when the best is unaffordable?79
Research in Brief78
A women-focused matrix mentorship programme in gastroenterology78
Dangerous Medicine78
CEND-1: a game changer for pancreatic cancer chemotherapy?76
An unusual complication after a variceal glue injection74
0.03697681427002